Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”

This communication responds to the Letter to the Editor [1], where noticeably Messrs. Brian Hassett, Steven Vicik, and Brian Fitzpatrick from Pfizer Biotech contended that a particular glycan profile, presented in comparison to different profiles, does not correspond to the historical profile of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Immunology Research 2018-01, Vol.2018 (2018), p.1-3
Hauptverfasser:	Flores-Ortiz, Luis F., Medina-Rivero, Emilio, Molina-Pérez, Aaron, Pérez, Néstor O., Ramírez-Ibanez, Nancy D., Salazar-Flores, Rodolfo D., Perdomo-Abúndez, Francisco C., López-Morales, Carlos A., Miranda-Hernández, Mariana P., Revilla-Beltri, Jorge
Format:	Artikel
Sprache:	eng
Schlagworte:	Antirheumatic Agents Autoimmune Diseases Biosimilar Pharmaceuticals Chromatography Etanercept Humans Immunology Letter to the Editor Mass spectrometry Medical treatment Scientific imaging
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This communication responds to the Letter to the Editor [1], where noticeably Messrs. Brian Hassett, Steven Vicik, and Brian Fitzpatrick from Pfizer Biotech contended that a particular glycan profile, presented in comparison to different profiles, does not correspond to the historical profile of the reference medicinal product of etanercept (Enbrel®), as it is exposed.
ISSN:	2314-8861 2314-7156
DOI:	10.1155/2018/6156024